Jun 1, 2026 06:00AM
May 29, 2026 06:00AM
May 27, 2026 05:00PM
May 27, 2026 05:00PM
May 21, 2026 06:00AM
May 13, 2026 01:27PM
May 6, 2026 06:00AM BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
Apr 29, 2026 06:00AM
Apr 29, 2026 06:00AM
Feb 26, 2026 06:00AM
Jan 6, 2026 01:30PM
Dec 18, 2025 06:00AM
Dec 18, 2025 06:00AM
Dec 8, 2025 08:00AM BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Dec 7, 2025 06:00PM
Nov 26, 2025 06:00AM
Nov 26, 2025 06:00AM
Nov 20, 2025 06:00AM
Nov 6, 2025 06:00AM
Oct 13, 2025 06:00AM
Aug 29, 2025 06:00AM BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Aug 6, 2025 06:00AM
Jul 31, 2025 06:00AM
Jun 25, 2025 06:00AM
Jun 12, 2025 06:00AM
Jun 11, 2025 04:05PM
Jun 11, 2025 04:05PM
May 31, 2025 08:00AM BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
May 14, 2025 04:05PM
May 7, 2025 06:00AM
Mar 4, 2025 06:00AM
Feb 27, 2025 06:00AM
Dec 27, 2024 06:01AM
Dec 27, 2024 06:00AM
Dec 9, 2024 08:30PM BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
Nov 19, 2024 07:00AM
Nov 12, 2024 06:00AM
Oct 16, 2024 06:00AM
Sep 26, 2024 06:21PM
Aug 26, 2024 06:00AM
Aug 7, 2024 06:00AM
Jun 14, 2024 06:00AM BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
May 8, 2024 06:00AM
Apr 23, 2024 06:00AM
Mar 14, 2024 04:30PM
Mar 14, 2024 04:28PM
Mar 14, 2024 10:12AM
Mar 7, 2024 05:19PM
Feb 27, 2024 06:00AM BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
Feb 26, 2024 06:00AM

322,084 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All